Priporočila za obravnavo diareje ob sistemskem onkološkem zdravljenju
Recommendations for diarrhea in systemic oncology treatment
Keywords:
diarrhea, patients, oncological patients, systemic treatmentAbstract
Diarejo definiramo kot pogosto odvajanje redkega, neformiranega ali vodenega blata več kot trikrat v 24 urah. Je eden izmed najpogostejših neželenih simptomov, s katerimi se srečujejo onkološki bolniki. Diareja lahko vodi v dehidracijo, elektrolitske in metabolne motnje, ledvično odpoved, v hudih oblikah tudi v hemodinamsko nestabilnost, ki zahteva hospitalizacijo. Ovira lahko nemoten potek specifičnega onkološkega zdravljenja z vplivom na kvaliteto življenja bolnikov, zmanjšano komplianco za zdravljenje in krajše preživetje. Splošna priporočila za obravnavo diareje ob onkološkem zdravljenju so bila prvič objavljena leta 1998, dopolnjena in prilagojena so izšla leta 2004 v reviji Journal of Clinical Oncology (1). Zaenkrat še ni posodobljenih, mednarodno sprejetih navodil. Prispevek povzema priznana in splošno sprejeta priporočila, z razlikovanjem obravnave diareje ob zdravljenju s citostatiki in tarčnimi zdravili.Abstract (Eng)
Diarrhea is defined as frequent passages of loose, unformed or liquid stool more than three times in 24 hours. It is one of the most common undesirable symptoms, which oncology patients face. Diarrhea can lead to dehydration, electrolytic and metabolic disorders, kidney failure and in severe cases also hemodynamic instability, which requires hospitalisation. The problem can affect the uninterrupted course of a specific cancer treatment and influence the quality of life of patients, reduce compliance to treatment and shorten the survival period. General recommendations for diarrhea in cancer treatment were first published in 1998, amended and adapted in 2004 in the Journal of Clinical Oncology (1). So far there are no updated, internationally accepted instructions. The article summarises the recognised and generally adopted recommendations, with differences in treatments of diarrhea with cytostatic and target medications.Downloads
Published
How to Cite
Issue
Section
License
The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.
This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.